- Home
- COCH vs INTS Comparison
COCH vs INTS Comparison
Compare COCH & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- INTS
- Stock Information
- Founded
- COCH 1995
- INTS 2012
- Country
- COCH United States
- INTS United States
- Employees
- COCH N/A
- INTS N/A
- Industry
- COCH Blank Checks
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- COCH Finance
- INTS Health Care
- Exchange
- COCH Nasdaq
- INTS Nasdaq
- Market Cap
- COCH 29.8M
- INTS 33.4M
- IPO Year
- COCH N/A
- INTS 2023
- Fundamental
- Price
- COCH $1.48
- INTS $2.23
- Analyst Decision
- COCH Strong Buy
- INTS Strong Buy
- Analyst Count
- COCH 3
- INTS 3
- Target Price
- COCH $8.00
- INTS $8.50
- AVG Volume (30 Days)
- COCH 26.8K
- INTS 26.6K
- Earning Date
- COCH 04-01-2025
- INTS 03-13-2025
- Dividend Yield
- COCH N/A
- INTS N/A
- EPS Growth
- COCH N/A
- INTS N/A
- EPS
- COCH N/A
- INTS N/A
- Revenue
- COCH $278,000.00
- INTS N/A
- Revenue This Year
- COCH N/A
- INTS N/A
- Revenue Next Year
- COCH $19.76
- INTS N/A
- P/E Ratio
- COCH N/A
- INTS N/A
- Revenue Growth
- COCH 15.35
- INTS N/A
- 52 Week Low
- COCH $1.17
- INTS $1.50
- 52 Week High
- COCH $11.46
- INTS $5.94
- Technical
- Relative Strength Index (RSI)
- COCH 45.07
- INTS 49.26
- Support Level
- COCH $1.39
- INTS $1.84
- Resistance Level
- COCH $1.62
- INTS $2.27
- Average True Range (ATR)
- COCH 0.13
- INTS 0.28
- MACD
- COCH 0.00
- INTS -0.01
- Stochastic Oscillator
- COCH 31.03
- INTS 56.36
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing innovative medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.